

From 0 to 300K Sessions: Is Psychedelic Therapy The Ultimate Treatment for Mental Health Issues?
Sep 6, 2023
Dylan Beynon, CEO of Mindbloom, talks about starting the company and the impact of Ketamine and MDMA therapy. They discuss pricing, the largest clinical study, and Dylan's personal opinion on the therapies. They also touch on Vipassana Meditation and where to find more information about Mindbloom.
Chapters
Transcript
Episode notes
1 2 3 4 5 6
Introduction
00:00 • 2min
Starting Mindbloom: A Journey Towards Mental Health Transformation
02:28 • 3min
MDMA Therapy vs Recreational Use
05:49 • 8min
Psychedelic Therapy Treatment: Cost, Structure, and Features
13:30 • 2min
Psychedelic Therapy: Availability and Potential
15:07 • 19min
Financial Aspects of Psychedelic Therapy and Capital Allocation Strategy
34:03 • 3min